WASHINGTON, Oct. 30 -- Drug Enforcement Administration has issued a rule called: Schedules of Controlled Substances: Placement of Centanafadine in Schedule III.
The rule was published in the Federal Register on Oct. 30 by Heather Achbach, Federal Register Liaison Officer, Drug Enforcement Administration.
Summary: On July 24, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder in adults and pediatric patients aged 6 years and older, weighing at least 20 kg. The Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place centanafadine, chemi...